FDA Approves Brain Tumor Warning for Depo-Provera After Pfizer Lawsuit Pressure

The Food and Drug Administration approved a label change for Pfizer查看公司主页's birth control shot Depo-Provera查看药品详情 on Friday, adding a warning about the risk of meningioma (搜索)搜索该疾病, a tumor in the lining of the brain. The regulatory action comes as Pfizer faces a federal lawsuit involving more than 1,000 women who claim the company knew about the brain tumor (搜索)搜索该疾病 risk but failed to warn patients and healthcare providers.

The label revision follows emerging evidence linking long-term use of Depo-Provera查看药品详情 (medroxyprogesterone acetate查看药品详情) to a higher likelihood of developing meningiomas — tumors that, while often benign, can cause serious neurological effects such as seizures (搜索)搜索该疾病, vision impairment (搜索)搜索该疾病, and headaches (搜索)搜索该疾病. Studies have suggested that women who use Depo-Provera for extended periods may face a significantly increased risk of these tumors compared with users of other contraceptives.

Regulatory Timeline and International Context

The FDA's decision represents a reversal from its earlier position. In February 2024, Pfizer查看公司主页 submitted an application to add a meningioma (搜索)搜索该疾病 warning to Depo-Provera查看药品详情's label, but the FDA denied the request, stating that "the findings of the available observational studies alone do not support the addition of a warning on Meningioma risk to medroxyprogesterone acetate查看药品详情 (MPA)-containing products."

Pfizer查看公司主页 then amended and resubmitted its application in June 2025, which the FDA approved this month. The approval "provides for the addition of information related to Meningioma (搜索)搜索该疾病 risk" on the drug's label for two versions of the injection — Depo-Provera查看药品详情 CI and Depo-Subq Provera 104.

The U.S. label change brings American prescribing information in line with international regulatory practices. In 2024, the European Medicines Agency (搜索)搜索该词条 added meningioma (搜索)搜索该疾病 as a "possible side effect" of drugs with high doses of medroxyprogesterone acetate查看药品详情. That same year, Canada's label for the drug was updated to include meningioma in its "warnings and precautions" section, stating that "meningiomas have been reported following long-term administration of progestins, including medroxyprogesterone acetate." In January, South Africa's drug regulatory agency also recommended updating the drug label for MPA to include meningioma risk.

Ongoing Federal Litigation

The FDA's action occurs amid growing litigation alleging that Pfizer查看公司主页 did not adequately warn patients and healthcare providers about meningioma (搜索)搜索该疾病 risk. In the ongoing federal multidistrict litigation (MDL) centralized before Judge M. Casey Rodgers in the Northern District of Florida, plaintiffs have alleged failure-to-warn and design defect claims against Pfizer and other manufacturers. As of early December 2025, thousands of claims have been consolidated, with case counts in the MDL climbing steadily over the past year.

The lawsuit points to several studies dating as far back as 1983 showing a link between progesterone查看药品详情 and meningioma (搜索)搜索该疾病, arguing these studies created an "unassignable duty to investigate," and that Pfizer查看公司主页 should have studied the risks associated with Depo-Provera查看药品详情 sooner. Progestin查看药品详情 is a synthetic version of progesterone.

One of the central legal questions has been whether the FDA's prior rejection of Pfizer查看公司主页's proposed label change in 2024 preempts state-law failure-to-warn claims. Courts have been weighing whether that regulatory history affects plaintiffs' ability to proceed with their claims.

Clinical Impact and Patient Population

According to the Centers for Disease Control and Prevention (搜索)搜索该公司, 1 in 4 sexually active women in the United States have used Depo-Provera查看药品详情. Black women use it at nearly double the national rate. The Depo-Provera regimen consists of a progestin查看药品详情 injection given every three months.

Meningiomas are usually not cancerous — meaning they don't spread to other parts of the body — but they can be harmful depending on their size and where they grow. The overall risk of developing a meningioma (搜索)搜索该疾病 remains small: About 39,000 meningiomas are diagnosed each year in the U.S.

Company and Legal Response

In a statement to NBC News, a Pfizer查看公司主页 spokesperson said the "label update reflects a recent decision by the FDA to approve the warning, which the agency had earlier denied." The company added: "Pfizer stands behind the safety and efficacy of Depo-Provera查看药品详情, which has been used by millions of women worldwide and remains an important treatment option for women seeking to manage their reproductive health."

Lawyers for the women suing Pfizer查看公司主页 responded: "For years, Pfizer misled doctors, patients and the FDA about Depo-Provera查看药品详情's link to meningiomas, resulting in the needless suffering of thousands of women who developed these dangerous brain tumors. … We applaud the FDA in finally requiring this label change to better inform and protect women."

The judge has yet to issue a decision in the case against Pfizer查看公司主页 in the United States. With the MDL now containing well over a thousand individual claims alleging neurological harm, the litigation continues to evolve as courts address dispositive motions, case management schedules, and preparations for bellwether trials.